These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 23035454)

  • 21. Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.
    Violini S; D'Ascenzo S; Bagnoli M ; Millimaggi D; Miotti S; Canevari S; Pavan A; Dolo V
    J Exp Clin Cancer Res; 2004 Mar; 23(1):83-91. PubMed ID: 15149155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
    Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small interfering RNA-mediated silencing of heat shock protein 27 (HSP27) Increases chemosensitivity to paclitaxel by increasing production of reactive oxygen species in human ovarian cancer cells (HO8910).
    Song TF; Zhang ZF; Liu L; Yang T; Jiang J; Li P
    J Int Med Res; 2009; 37(5):1375-88. PubMed ID: 19930842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and evaluation of a novel TPGS-mediated paclitaxel-loaded PLGA-mPEG nanoparticle for the treatment of ovarian cancer.
    Lv W; Cheng L; Li B
    Chem Pharm Bull (Tokyo); 2015; 63(2):68-74. PubMed ID: 25451039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An experimental study of ovarian cancer imaging and therapy by paclitaxel-loaded phase-transformation lipid nanoparticles combined with low-intensity focused ultrasound.
    Gao Y; Chen S; Li W; Wang H; Xiao K; Wu L; Li Y; Li H; Li H; Zhu Y
    Biochem Biophys Res Commun; 2018 Sep; 504(1):203-210. PubMed ID: 30180951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
    Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
    Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo establishment and characterization of a paclitaxel-resistant human ovarian cancer cell line showing enhanced growth properties and drug-resistance only in vivo.
    Okugawa K; Kobayashi H; Hirakawa T; Sonoda T; Ogura T; Nakano H
    J Cancer Res Clin Oncol; 2004 Mar; 130(3):178-86. PubMed ID: 14655049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BAD partly reverses paclitaxel resistance in human ovarian cancer cells.
    Strobel T; Tai YT; Korsmeyer S; Cannistra SA
    Oncogene; 1998 Nov; 17(19):2419-27. PubMed ID: 9824152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
    Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
    Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kuguacin J isolated from bitter melon leaves modulates paclitaxel sensitivity in drug-resistant human ovarian cancer cells.
    Pitchakarn P; Umsumarng S; Mapoung S; Ting P; Temviriyanukul P; Punfa W; Pompimon W; Limtrakul P
    J Nat Med; 2017 Oct; 71(4):693-702. PubMed ID: 28639112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
    Tong L; Chen W; Wu J; Li H
    Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of estrogen or progesterone combined with paclitaxel on human ovarian cancer cell growth and Drosha expression].
    Yang Y; Han K; Xie Y
    Zhonghua Zhong Liu Za Zhi; 2015 Aug; 37(8):578-84. PubMed ID: 26714597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
    George JA; Chen T; Taylor CC
    Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy.
    Alemi A; Zavar Reza J; Haghiralsadat F; Zarei Jaliani H; Haghi Karamallah M; Hosseini SA; Haghi Karamallah S
    J Nanobiotechnology; 2018 Mar; 16(1):28. PubMed ID: 29571289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts.
    Ye L; He J; Hu Z; Dong Q; Wang H; Fu F; Tian J
    Food Chem Toxicol; 2013 Feb; 52():200-6. PubMed ID: 23149094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modelling of Paclitaxel Conjugated with Carbon Nanotubes as an Antitumor Agent for Cancer Therapy.
    Al Garalleh H; Algarni A
    J Biomed Nanotechnol; 2020 Feb; 16(2):224-234. PubMed ID: 32252883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides.
    Sun J; Jiang L; Lin Y; Gerhard EM; Jiang X; Li L; Yang J; Gu Z
    Int J Nanomedicine; 2017; 12():1517-1537. PubMed ID: 28280323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted and controlled anticancer drug delivery and release with magnetoelectric nanoparticles.
    Rodzinski A; Guduru R; Liang P; Hadjikhani A; Stewart T; Stimphil E; Runowicz C; Cote R; Altman N; Datar R; Khizroev S
    Sci Rep; 2016 Feb; 6():20867. PubMed ID: 26875783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A proteomic approach to paclitaxel chemoresistance in ovarian cancer cell lines.
    Di Michele M; Della Corte A; Cicchillitti L; Del Boccio P; Urbani A; Ferlini C; Scambia G; Donati MB; Rotilio D
    Biochim Biophys Acta; 2009 Feb; 1794(2):225-36. PubMed ID: 18973835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Preparation, characterization of paclitaxel-loaded Pluronic P105 polymeric micelles and in vitro reversal of multidrug resistant tumor].
    Wang YZ; Fang XL; Li YJ; Zhang ZW; Han LM; Sha XY
    Yao Xue Xue Bao; 2008 Jun; 43(6):640-6. PubMed ID: 18822969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.